Introduction
Community pharmacists have frequent face-to-face interactions with patients at every medication fill. 1, 2 Many of these interactions can be used to introduce patients to medication therapy management (MTM) services. One service offered through MTM is the comprehensive medication review (CMR), which consists of a full review of all medications and past medication history. 1, 2 If a medication problem is identified, a targeted medication review (TMR) will occur to resolve this specific medication-related problem. 1, 3, 4 When providing CMRs and TMRs, pharmacists focus on optimal medication regimens to improve patient outcomes. 2 The Asheville Project ™ extensively evaluated the implementation of MTM and its effects on patient outcomes finding improvements in hypertension, dyslipidemia, asthma, and diabetic patients. [5] [6] [7] Despite the benefits of increased patient interaction and data suggesting MTM correlates to increased patient outcomes, there is still a significant financial barrier to implementing MTM services. [8] [9] [10] A method to determine the financial impact of an MTM program is return on investment (ROI). This method is not widely used to evaluate pharmacy services in the profession. ROI represents revenue generated through MTM interventions versus investment in the MTM program. 1, 8, 11 This is significant to obtain since 79% of pharmacies do not know their ROI, and ROI is not typically used as a study parameter. 1 It is important for pharmacists to be more cost conscious in order to meet the ever-increasing financial demands placed on community pharmacists and to encourage implementation of sustainable business models. 1, 8 A regional chain pharmacy in North Carolina experimented with different MTM models. One model utilized was a ''hub and spoke'' model in which select pharmacists traveled to designated pharmacy locations and conducted MTM services for those locations. Another model utilized was an ''integrated'' model in which all pharmacists conduct MTMs in their own pharmacy and community as part of the pharmacy workflow.
Currently, there is no literature published comparing the ROI of each model.
Objective
The purpose of this study is to compare the ROI of 2 MTM practice models.
Methods
This study was a multisite, retrospective cohort analysis of 76 community pharmacies within Kerr Drug, a regional chain in North Carolina. Patients who received a CMR or TMR in calendar years 2010 or 2012 were included. Excluded from analysis were nonpaid claims and claims from the calendar year 2011, in which both models were deployed simultaneously. Revenue data generated from CMRs and TMRs were collected from a web-based MTM service provider. All paid claims were included. This study was approved by the University of North Carolina Institutional Review Board.
Revenue associated with a TMR correlated to a US$10 or US$20 reimbursement. Revenue associated with a CMR correlated to a US$50 or US$75 reimbursement. Patient or prescriber refusals yielded US$0 or US$2 in reimbursement.
The investment by the pharmacy was calculated using 2 elements: pharmacist average salary and average time for completion for MTM encounters. The average hourly salary in 2010 was US$52.43, obtained from the regional pharmacy chain's corporate office. 4 The average hourly salary in 2012 was US$54.54. This was estimated utilizing trends data from the National Community Pharmacist's Association (NCPA) and the Bureau of Labor Statistics, which suggested a conservative 2% increase in salary from 2010 to 2011 and again from 2011 to 2012.
12,13
The average time for completion used to calculate ROI was 20 minutes for a TMR and 30 minutes for a CMR. These values were designated based on prior research 11 and after consultation with 2 MTM service providers for accepted practice.
Analysis
ROI was calculated for both the 2010 hub and spoke and 2012 integrated practice models by totaling each year's revenue and subtracting total investment. Pharmacy revenue was calculated by tallying payment for the total number of CMRs and TMRs within each 12-month period (Table 1) . Pharmacy investment was calculated by determining the total amount of time invested by pharmacists to conduct both TMRs and CMRs, in each model year, independently. The total number of CMRs and TMRs completed each year were multiplied by 20 minutes and 30 minutes, respectively. The pharmacist average hourly salary for each model year was multiplied by the total amount of pharmacist time, in hours, invested to complete TMRs and CMRs reimbursed to the pharmacy.
Results
The hub and spoke model yielded 8757 claims to 4089 patients resulting in 1471 CMRs and 7286 TMRs. A total of 3164.17 pharmacist hours were invested, 735.5 pharmacist hours to CMRs, and 2428.67 hours to TMRs. At US$52.43 per hour, US$165 897.26 was invested in MTM services for the hub and spoke model. Comparatively, the integrated model yielded 13 730 claims in total to 4896 patients or 3441 CMRs and 10 289 TMRs. A total of 1720.5 pharmacist hours were invested in CMRs and 3429.67 pharmacist hours were invested in TMRs. This resulted in a total of 5150.17 pharmacist hours at US$54.54, an hour investing US$280.890.09 in MTM services for the integrated model (Table 1) . Abbreviations: CMRs, comprehensive medication reviews; TMRs, targeted medication reviews; ROI, return on investment; MTM, medication therapy management.
Pharmacy revenue through reimbursements was calculated by summing the reimbursements from the various types of CMRs and TMRs. This resulted in a total reimbursement of US$173 498.00 for the hub and spoke model and US$302 963.00 for the integrated model (Table 1) . The hub and spoke model yielded a net gain of US$7600.74, with a 4.6% ROI and a ratio of 1:12.
Comparatively, the integrated model yielded a net gain of US$22 072.91, with a 7.9% ROI and a ratio of 1:21 (Table 1) .
Discussion
The integrated model of MTM resulted in a higher ROI than the traditional hub and spoke model. Across 76 stores this equates, on average, to US$100.00 net revenue per store in the hub and spoke model and US$290.43 net revenue in the integrated model. Although such revenue would not be considered as a significant revenue source to individual pharmacy practices, the data demonstrates MTM services can provide revenue for the pharmacy to off set the cost of conducting MTM. This trial suggests that the additional pharmacy investment in pharmacist hours can be overcome by the reimbursements for services. While both models of MTM presented a positive ROI, integrated models may have a greater potential for higher ROIs by maximizing the efficiency of daily workflow, which may afford an opportunity to increase the number of patient encounters and thus reimbursable claims. This is the first study looking at ROI for MTM services across a regional community pharmacy chain, showing feasibility and sustainability and contrasting different execution models of MTM. A study by Truong et al 14 analyzed MTM in a safety net clinic and found a high ROI of 1:5 to 1:25. However, only 246 received MTM over 4 years, and results have limited translation to the community pharmacy setting. McDonough et al 9 showed in 1 independent pharmacy that MTM services resulted in a net financial gain of US$3.28 over 16 months. The authors concluded a very modest ROI in 1 community pharmacy practice compared to the US$100.00 per store in 2010 and US$290.43 per store in 2012 found in the current study. Additional research is needed to determine longterm sustainability of MTM services.
Limitations
It is prudent to mention several limitations of this study. Firstly, direct observational data would have provided great insight into pharmacist ''time for completion'' for each MTM intervention. A prospective review should be considered to closely follow, rather than estimate, the exact time for completion of interventions made by pharmacists. The time estimates of 20 and 30 minutes for TMR and CMR were based on Kerr Drug estimates, however examples from other literature would argue that the CMR time is low. In this study, it was assumed that time spent on a CMR or TMR was the same in both models. We did not account for pharmacist travel time or no show rates for patients in the hub and spoke model. If both of these were considered in the analysis, the ROI would be much higher for the integrated model. This study is limited by the fact that MTM practices were evaluated at one regional pharmacy chain. Future studies would benefit from evaluating MTM models in different geographical regions in which reimbursement, payment, and implementation models as well as the pharmacists' scope of practice may differ.
This study is also limited by the lack of ability to collect auxiliary revenue generated at the pharmacy, secondary to MTM services. These include new and refilled prescriptions, over-the-counter sales, and front-end items sold to the patient. Additionally, many of the community pharmacists in this analysis provided additional services including blood pressure screening and assessment, cholesterol and blood glucose point of care testing, and immunizations, all representing additional revenue sources. It is difficult to determine whether patients would have participated in the aforementioned revenue sources in response to pharmacist provided MTM services without purposeful and concurrent data collection. Future research may be warranted to capture additional revenue sources secondary to MTM and to evaluate axillary contributions to ROI. Finally, the availability of MTM opportunities and reimbursement programs may limit the generalizability of the study due to large variances by state, region, payer, and contract year.
Conclusion
The integrated MTM model showed an increase in pharmacist provided MTM interventions resulting in a higher ROI. However, both models resulted in a positive ROI showing MTM services can be cost effective with varying practice models. 
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